1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
BDH Industries Limited

BDH Industries Limited

BBSE:BDH
424.00
INR
-20.35
(-4.58%)
20.34EPS
23.92P/E
2.80BMarket Cap
BDH Industries Limited
BSE:BDH
(Bombay Stock Exchange)

Recent

price

424.00

P/E

ratio

23.92

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
64.82
68.96
69.76
73.19
76.8
79.02
74.34
69.63
87.49
101.34
97.84
119.07
128.25
147.36
112.7
163.72
173.19
Revenue per Share
1.35
1.89
2.91
3.99
4.46
5.6
5.8
6.54
8.39
10.32
11.05
12.55
14.25
17.14
16.11
18.78
20.34
Basic EPS, GAAP
6.7
14.74
7.75
5.93
10.51
-0.65
1.17
-0.97
-6.94
19.62
1.34
4.86
10.92
-6.54
25.28
-4.24
- -
Free Cash Flow per Basic Share
- -
0.58
0.7
1.16
1.41
2.05
2.41
2.41
2.71
3.32
2.5
3
3.6
4
4.5
4.5
- -
Dividend per Share
35.07
36.23
37.95
40.16
41.83
47.41
50.78
54.29
59.65
66.42
74.81
84.39
95
107.96
119.43
133.77
- -
Book Value per Share
35.07
36.23
37.95
40.16
41.83
47.41
50.78
54.29
59.65
66.42
74.81
84.39
95
107.96
119.43
133.77
- -
Tangible Book Value per Share
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Basic Weighted Avg Shares
373
397
402
421
442
455
428
401
504
583
563
686
738
848
649
943
997
Sales/Revenue/Turnover
5.3
6.04
6.34
6.88
6.92
7.36
9.55
11.5
12.26
13.73
13.71
12.32
14.06
13.97
16.49
13.8
14.42
Operating Margin (%)
7
10
7
8
7
7
7
8
8
10
8
6
6
6
9
9
9
Depreciation Expense
8
11
17
23
26
32
33
38
48
59
64
72
82
99
93
108
117
Net Income, GAAP
24.37
32.45
32.65
32.51
32.28
32.94
33.06
27.29
26.19
26.82
27.28
24.4
25.87
25.54
25.62
28.83
28.8
Effective Tax Rate (%)
2.08
2.74
4.16
5.45
5.81
7.09
7.8
9.39
9.59
10.18
11.29
10.54
11.11
11.63
14.29
11.47
11.74
Profit Margin (%)
65
68
80
96
118
110
85
101
131
179
236
295
359
419
498
598
- -
Working Capital
11
- -
- -
- -
- -
- -
8
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
202
209
219
231
241
273
292
313
343
382
431
486
547
622
688
770
- -
Total Equity
2.52
3.85
5.82
7.07
7.51
9.12
8.84
8.7
10.57
12.35
11.33
13.11
13.91
13.5
11.3
12.42
- -
Return on Invested Capital (%)
2.52
4.52
6.38
7.58
8.59
9.9
9.59
10.33
12.1
13.6
13.26
14.44
15.08
15.34
13.27
14.6
- -
Return on Capital (%)
3.88
5.29
7.83
10.22
10.89
12.56
11.8
12.45
14.73
16.37
15.64
15.76
15.89
16.89
14.17
14.84
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
20
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
2,449
2,031
2,802

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
798
- -
Cash, Cash Equivalents & STI
- -
290
- -
Accounts Receivable, Net
- -
316
- -
Inventories
- -
54
- -
Total Current Liabilities
- -
200
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
20
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.95%
12.33%
12%
Free Cash Flow
-70.35%
-75%
-116.75%
Net Income, GAAP
13.26%
11.61%
16.61%
Sales/Revenue/Turnover
9.18%
13.21%
45.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
163
162
162
178
649
2026
186
190
293
290
943
2027
224
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.72
4.18
4.88
4.32
16.11
2026
3.17
4.55
6.06
5
18.78
2027
4.73
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
4.5
2026
- -
- -
- -
- -
4.5
2027
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
BDH Industries Limited (BDH.BO), founded in 1935 as Bombay Drug House and headquartered in Mumbai, India, manufactures and exports a wide range of therapeutic pharmaceutical formulations; its core products encompass antifungals, antibiotics, anticancer agents, antidiabetics, antidepressants, antiulcerants, antimalarials, anti-inflammatories, analgesics, antispasmodics, anti-tuberculosis drugs, cardiovascular medications, dermatologicals, NSAIDs, psychotropics, trichologicals, vitamins and minerals, as well as skin protectives, smootheners, and specialized offerings like SOULFIL for erectile dysfunction treatment; the company operates as a full-service contract manufacturing organization (CMO) providing tablets, capsules, topical creams and ointments, injections, oral suspensions, eye drops, dry syrups, and associated packaging solutions across pharmaceuticals and oncological products. BDH Industries serves domestic and international markets, with operations in India and exports to global destinations, and maintains a renewable energy segment through two wind turbines totaling 0.8 MW capacity in Jaisalmer, Rajasthan. In recent developments, the company continues steady growth as a reliable CMO partner for leading pharmaceutical firms, held its 35th Annual General Meeting proceedings released on August 7, 2025, scheduled a Board meeting for November 12, 2025 to consider financial results, and sustains stable promoter shareholding at approximately 49.7% as of September 2025.